PAX5 and cholangiocarcinoma: The present research uncovers that PAX5/PSMA3-AS1/miR-376a-3p/LAMC1 expedites cholangiocarcinoma deterioration, and PSMA3-AS1 is hopeful to become an intervention target for cholangiocarcinoma.